Prince Pharmaceutical Co., Ltd.
Prince Pharmaceutical Co., Ltd. manufactures and sells vitamin B1 active pharmaceutical ingredients (APIs) in Taiwan, Japan, Korea, and internationally. The company also offers health food and medicines; vitamin c tablets, vitamin b complex tablets, natto and rhodiola extract capsules, probiotic sachets, and plant extract capsules; and API products comprising felbinac, aldioxa, tulobuterol, ufena… Read more
Prince Pharmaceutical Co., Ltd. (6935) - Total Assets
Latest total assets as of June 2025: NT$1.36 Billion TWD
Based on the latest financial reports, Prince Pharmaceutical Co., Ltd. (6935) holds total assets worth NT$1.36 Billion TWD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Prince Pharmaceutical Co., Ltd. - Total Assets Trend (2019–2024)
This chart illustrates how Prince Pharmaceutical Co., Ltd.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Prince Pharmaceutical Co., Ltd. - Asset Composition Analysis
Current Asset Composition (December 2024)
Prince Pharmaceutical Co., Ltd.'s total assets of NT$1.36 Billion consist of 27.1% current assets and 72.9% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 7.6% |
| Accounts Receivable | NT$116.63 Million | 8.7% |
| Inventory | NT$141.47 Million | 10.5% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$450.00K | 0.0% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how Prince Pharmaceutical Co., Ltd.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Prince Pharmaceutical Co., Ltd.'s current assets represent 27.1% of total assets in 2024, a decrease from 28.4% in 2019.
- Cash Position: Cash and equivalents constituted 7.6% of total assets in 2024, down from 15.1% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is inventory at 10.5% of total assets.
Prince Pharmaceutical Co., Ltd. Competitors by Total Assets
Key competitors of Prince Pharmaceutical Co., Ltd. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biostar Pharmaceuticals Inc
PINK:BSPM
|
USA | $41.43 Million |
|
High Sierra Technologies Inc
PINK:HSTI
|
USA | $10.70K |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423
|
China | CN¥12.75 Billion |
Prince Pharmaceutical Co., Ltd. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Prince Pharmaceutical Co., Ltd. generates 0.51x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Prince Pharmaceutical Co., Ltd. is currently not profitable relative to its asset base.
Prince Pharmaceutical Co., Ltd. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.63 | 1.70 | 1.59 |
| Quick Ratio | 0.93 | 1.05 | 0.80 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$155.74 Million | NT$ 148.24 Million | NT$ 111.52 Million |
Prince Pharmaceutical Co., Ltd. - Advanced Valuation Insights
This section examines the relationship between Prince Pharmaceutical Co., Ltd.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.57 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | -4.4% |
| Total Assets | NT$1.35 Billion |
| Market Capitalization | $10.61 Million USD |
Valuation Analysis
Below Book Valuation: The market values Prince Pharmaceutical Co., Ltd.'s assets below their book value (0.01 x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Prince Pharmaceutical Co., Ltd.'s assets decreased by 4.4% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Prince Pharmaceutical Co., Ltd. (2019–2024)
The table below shows the annual total assets of Prince Pharmaceutical Co., Ltd. from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$1.35 Billion | -4.44% |
| 2023-12-31 | NT$1.41 Billion | +8.18% |
| 2022-12-31 | NT$1.30 Billion | +1.06% |
| 2021-12-31 | NT$1.29 Billion | +6.24% |
| 2020-12-31 | NT$1.21 Billion | +5.05% |
| 2019-12-31 | NT$1.16 Billion | -- |